MusclePharm Gets Slammed Back Down to Unprofitable Performance

Just when MusclePharm had profitability on its mind, the sports nutrition company gets slammed back down to face its historical reality. In this episode, I'll provide you with various insights pulled from the MusclePharm (OTCMKTS: MSLP) 2021Q2 earnings report, earnings call, and additional publicly-disclosed information released by the company. They will collectively be used to update you on the sales performance and profitability plan of action at MusclePharm. I will also provide an extensive update on the energy drinks project that includes MP Performance Energy and FitMiss. This includes a longer term outlook on segment-level revenue expectation and details of categorical challenges and potential land mines. Finally, I will express my confusion on the MusclePharm energy drink instead of the Combat protein RTD beverage strategy.